Phase II Study of Doxorubicin and Avastin® in Sarcoma.

Sarcoma Clinical Trial

Official title:

Phase II Study of Doxorubicin and Avastin® for Patients With Advanced Soft-tissue Sarcomas.

Clinical Trial Details — Status: Terminated

Administrative data

• NCT number: NCT00755261
• Other study ID #: J07133
• Secondary ID: NA_00013238AVF38
• Status: Terminated
• Phase: Phase 2
• First received: September 17, 2008
• Last updated: May 7, 2015
• Start date: September 2008
• Est. completion date: November 2010

Study information

• Verified date: May 2015
• Source: Sidney Kimmel Comprehensive Cancer Center
• Contact: n/a
• Is FDA regulated: No
• Health authority: United States: Food and Drug Administration
• Study type: Interventional

Clinical Trial Summary

This research is being done to find out if adding a drug called Avastin to an already approved regimen used for soft-tissue sarcoma, Doxorubicin, will improve overall survival, and slow disease progression. The study will also evaluate the overall safety of combining these drugs. It is not known if combining these drugs will improve outcome. Avastin has been approved for the treatment of metastatic carcinoma of the colon or rectum. It is not approved for the treatment of soft-tissue sarcoma when added to Doxorubicin.

Description:

The rationale for this trial is to improve the efficacy of prototypical anti-sarcoma chemotherapeutic regimen Doxorubicin when combined with Avastin®. Soft tissue sarcomas are highly vascular tumors and are therefore ideally suited to trials combining angiogenic inhibitors with chemotherapy. Several studies have revealed correlations between prognosis and surrogates for angiogenesis, including microvessel density, and circulating VEGF and basic fibroblast growth factor (bFGF). The aim of this study is to evaluate the safety and efficacy of Avastin® in combination with Doxorubicin for the treatment of advanced soft-tissue sarcomas.

Recruitment information / eligibility

• Status: Terminated
• Enrollment: 4
• Est. completion date: November 2010
• Est. primary completion date: September 2010
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

1. Pathologically confirmed intermediate or high grade locally advanced or metastatic soft tissue sarcoma.

2. The presence of measurable disease

3. Normal renal function (spot dipstick <2** or urine protein: creatinine ratio >1.0

4. Normal Hepatic function (total bilirubin within JOHC normal limits, transaminases (AST and ALT <3 times upper limit of normal

5. Hematologic parameters as defined as ANC >1500/mm³ and Platelets > 100,000/mm³.

6. Performance status 0-1 on ECOG scale

7. Use of effective means of contraception (men and women) in subjects of child-bearing age

8. No prior use of mesna, adriamycin, ifosfamide or Avastin®.

9. Baseline ECHO or MUGA with LVEF > or = 50-60%.

10. Age = 18

Exclusion Criteria:

1. Major surgery within 28 days

2. History of proteinuria > 1+

3. Current, recent (within 4 weeks of the first infusion of this study), or planned participation in an experimental drug study other than a Genentech-sponsored Avastin® cancer study

4. Inadequately controlled hypertension (defined as systolic blood pressure >150 and/or diastolic blood pressure > 100 mmHg on antihypertensive medications)

5. Any prior history of hypertensive crisis or hypertensive encephalopathy

6. New York Heart Association (NYHA) Grade II or greater congestive heart failure (see Appendix E)

7. History of myocardial infarction or unstable angina within 6 months prior to study enrollment

8. History of stroke or transient ischemic attack within 6 months prior to study enrollment

9. Symptomatic peripheral vascular disease

10. Significant vascular disease (e.g., aortic aneurysm, aortic dissection)

11. Evidence of bleeding diathesis or coagulopathy

12. Current or recent (within 10 days of enrollment) use of aspirin (>325 mg/day) or chronic use of other NSAIDs

13. Current, ongoing treatment with full-dose warfarin or its equivalent (i.e., unfractionated and/or low molecular weight heparin).

14. Known central nervous system or brain metastases

15. Major surgical procedure, open biopsy, or significant traumatic injury within 28 days prior to Day 0, anticipation of need for major surgical procedure during the course of the study

16. Core biopsy or other minor surgical procedure, excluding placement of a vascular access device, within 7 days prior to study enrollment

17. Pregnant (positive pregnancy test) or lactating

18. Proteinuria :creatinine (UPC) ratio = 1.0 at screening or Urine dipstick for proteinuria = 2+ (patients discovered to have =2+ proteinuria on dipstick urinalysis at baseline should undergo a 24 hour urine collection and must demonstrate = 1g of protein in 24 hours to be eligible).

19. History of abdominal fistula, gastrointestinal perforation, or intra-abdominal abscess within 6 months prior to Day 0

20. Serious, non-healing wound, ulcer, or bone fracture

21. Known hypersensitivity to any component of Avastin®

22. Inability to comply with study and/or follow-up procedures

Study Design

Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

• Sarcoma
• Soft Tissue Sarcoma

Intervention

Drug:
• Avastin
Combination of Avastin and doxorubicin. If initial 90 +/- 15 minute infusion of Avastin is tolerated without fever and chills, the 2nd dose may be infused over 60 +/- 10 minutes. If well tolerated, all subsequent infusions may be delivered over 30 +/- 10 minutes.
• Doxorubicin
The Day 1 6- hour continuous IV infusion must be done through a central venous catheter.

Locations

Country	Name	City	State
United States	Johns Hopkins SKCCC	Baltimore	Maryland

Sponsors (1)

Lead Sponsor	Collaborator
Sidney Kimmel Comprehensive Cancer Center

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	RECIST	Study was terminated because of low accrual.	6 month PFS	No